ӳ��ý

Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors.

Fang C, Lee KK, Nietupski R, et al. Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors. Bioorg Med Chem Lett. 2018;28(22):3529-3533. doi:10.1016/j.bmcl.2018.09.037

Identification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile.

Duvall JR, Bedard L, Naylor-Olsen AM, et al. Identification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile. ACS Infect Dis. 2017;3(5):349-359. doi:10.1021/acsinfecdis.6b00206

Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum.

Bopp S, Magistrado P, Wong W, et al. Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nat Commun. 2018;9(1):1769. doi:10.1038/s41467-018-04104-z

Inactivation of Plasmepsins 2 and 3 Sensitizes Plasmodium falciparum to the Antimalarial Drug Piperaquine.

Mukherjee A, Gagnon D, Wirth DF, Richard D. Inactivation of Plasmepsins 2 and 3 Sensitizes Plasmodium falciparum to the Antimalarial Drug Piperaquine. Antimicrob Agents Chemother. 2018;62(4). doi:10.1128/AAC.02309-17

Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway.

Nakasone MA, Lewis TA, Walker O, et al. Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway. Structure. 2017;25(12):1839-1855.e11. doi:10.1016/j.str.2017.10.007

Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.

Golfmann K, Meder L, Koker M, et al. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018;37(42):5682-5693. doi:10.1038/s41388-018-0380-3

A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML.

Gopal S, Lu Q, Man JJ, et al. A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML. Blood Adv. 2018;2(14):1680-1684. doi:10.1182/bloodadvances.2018020396

Studies toward the total synthesis of dihydrolycolucine. Preparation of AB and CEF ring fragments.

Cash BM, Prevost N, Wagner FF, Comins DL. Studies toward the total synthesis of dihydrolycolucine. Preparation of AB and CEF ring fragments. J Org Chem. 2014;79(12):5740-5. doi:10.1021/jo500878v

Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases.

Palomo V, Perez DI, Roca C, et al. Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. J Med Chem. 2017;60(12):4983-5001. doi:10.1021/acs.jmedchem.7b00395

Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates.

Youngsaye W, Vincent B, Hartland CL, et al. Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates. Bioorg Med Chem Lett. 2011;21(18):5502-5. doi:10.1016/j.bmcl.2011.06.105